NDC 61755-021

Praluent

Alirocumab

Praluent is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Regeneron Pharmaceuticals, Inc.. The primary component is Alirocumab.

Product ID61755-021_03a8dbf0-1310-4003-982e-9c4d9bed7896
NDC61755-021
Product TypeHuman Prescription Drug
Proprietary NamePraluent
Generic NameAlirocumab
Dosage FormInjection, Solution
Route of AdministrationSUBCUTANEOUS
Marketing Start Date2019-02-15
Marketing CategoryBLA / BLA
Application NumberBLA125559
Labeler NameRegeneron Pharmaceuticals, Inc.
Substance NameALIROCUMAB
Active Ingredient Strength150 mg/mL
Pharm ClassesPCSK9 Inhibitor [EPC],PCSK9 Inhibitors [MoA],Antibodies, Monoclonal [CS]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 61755-021-01

1 SYRINGE, GLASS in 1 CARTON (61755-021-01) > 1 mL in 1 SYRINGE, GLASS
Marketing Start Date2020-12-01
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Praluent" or generic name "Alirocumab"

NDCBrand NameGeneric Name
0024-5901Praluentalirocumab
0024-5902Praluentalirocumab
0024-5903Praluentalirocumab
0024-5904Praluentalirocumab
61755-020Praluentalirocumab
72733-5901PraluentPraluent
72733-5902PraluentPraluent
61755-021PraluentPraluent

Trademark Results [Praluent]

Mark Image

Registration | Serial
Company
Trademark
Application Date
PRALUENT
PRALUENT
86318389 4659691 Live/Registered
SANOFI BIOTECHNOLOGY
2014-06-24

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.